Drug
HMBD-001
HMBD-001 is a pharmaceutical drug with 3 clinical trials. Currently 3 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
3(100%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Active, not recruiting2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
active_not_recruiting267%
recruiting133%
Recent Activity
3 active trials
Showing 3 of 3
recruitingphase_1
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
NCT05910827
active_not_recruitingphase_1
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
NCT05057013
active_not_recruitingphase_1
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
NCT05919537
Clinical Trials (3)
Showing 3 of 3 trials
NCT05910827Phase 1
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
NCT05057013Phase 1
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
NCT05919537Phase 1
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3